Hjalmar et al. found that the average proportion of CD19+ B cells expressing CD25 in subjects with chronic lymphocytic leukemia was significantly higher than that in healthy controls, and the median treatment time of these patients was shorter than that of patients with CD25− B cells [20]. The gene discussed is IL2RA; the disease is B-cell chronic lymphocytic leukemia.